Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

NCT02605954 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

275

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1 Infection

Interventions

DRUG: E/C/F/TAF
DRUG: ABC/3TC
DRUG: Third Antiretroviral Agent

Sponsor

Gilead Sciences